Trial · NCT06202560
Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study
NCT06202560, Not applicable, Completed, Institute of Dermatology, Thailand; results first posted 2025-05-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study. Trials, record NCT06202560. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06202560
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study
- NCT number
- NCT06202560
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 11 participants, actual
- Lead sponsor
- Institute of Dermatology, Thailand
- Conditions
- Frontal Fibrosing Alopecia, Lichen Planopilaris of Scalp
- Interventions
- Tofacitinib 5 MG
- First posted
- 2024-01-11
- Last updated
- 2025-05-30
- Results first posted
- 2025-05-30
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effectiveness of Oral Tofacitinib in Recalcitrant Frontal Fibrosing Alopecia(FFA) | 16 weeks after taking oral Tofacitinib | The effectiveness of this study will be evaluated by comparing the Frontal Fibrosing Alopecia Severity Index (FFASI) (Max score = 100 and Min score = 0), Frontal Fibrosing Alopecia Severity Score (FFASS) (Max score = 25 and Min score = 0), and Lichen Planopilaris Activity Index (LPPAI) (Max score = 10 and Min score = 0) between week 0 (baseline week) and week 16. If a patient has a lower score on all of these indices, it means the treatment is more effective. In addition, two expert physicians will independently evaluate the photographs. The two evaluators will determine whether the patient's conditions have improved, remained stable, or worsened. |
| Secondary | Clinical & Investigation Safety of Oral Tofacitinib in Recalcitrant (FFA) | 16 weeks after taking oral Tofacitinib |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Effectiveness of Oral Tofacitinib in Recalcitrant Frontal Fibrosing Alopecia(FFA) | 16 weeks after taking oral Tofacitinib | The effectiveness of tofacitinib for FFA was assessed by comparing the Frontal Fibrosing Alopecia Severity Index (FFASI) (ranging from 0 to 100), Frontal Fibrosing Alopecia Severity Score (FFASS) (ranging from 0 to 25), and Lichen Planopilaris Activity Index (LPPAI) (ranging from 0 to 10) between baseline (week 0) and week 16. Lower scores across these indices indicated greater treatment effectiveness. Two independent dermatologists reviewed patient photographs to determine improvements. | score on a scale | MEDIAN |
| SECONDARY | Clinical & Investigation Safety of Oral Tofacitinib in Recalcitrant (FFA) | 16 weeks after taking oral Tofacitinib | participants | NUMBER |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Effectiveness of Oral Tofacitinib in Recalcitrant Frontal Fibrosing Alopecia(FFA) | Tofacitinib | FFASI at baseline (week 0) | 47.5 | Standard Deviation 13.25 | score on a scale |
| Effectiveness of Oral Tofacitinib in Recalcitrant Frontal Fibrosing Alopecia(FFA) | Tofacitinib | FFASI at week 16 | 44 | Standard Deviation 13.5 | score on a scale |
| Effectiveness of Oral Tofacitinib in Recalcitrant Frontal Fibrosing Alopecia(FFA) | Tofacitinib | FFASS at baseline (week 0) | 16.3 | Standard Deviation 4.07 | score on a scale |
| Effectiveness of Oral Tofacitinib in Recalcitrant Frontal Fibrosing Alopecia(FFA) | Tofacitinib | FFASS at week 16 | 15.9 | Standard Deviation 4.62 | score on a scale |
| Effectiveness of Oral Tofacitinib in Recalcitrant Frontal Fibrosing Alopecia(FFA) | Tofacitinib | LPPAI at baseline (week 0) | 1.83 | Standard Deviation 1.01 | score on a scale |
| Effectiveness of Oral Tofacitinib in Recalcitrant Frontal Fibrosing Alopecia(FFA) | Tofacitinib | LPPAI at week 16 | 1.33 | Standard Deviation 0.49 | score on a scale |
| Clinical & Investigation Safety of Oral Tofacitinib in Recalcitrant (FFA) | Tofacitinib | mild acne vulgaris | 4 | participants | |
| Clinical & Investigation Safety of Oral Tofacitinib in Recalcitrant (FFA) | Tofacitinib | hypercholesterolemia | 5 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tofacitinib | 11 | |
| Overall Study | COMPLETED | Tofacitinib | 11 | |
| Overall Study | NOT COMPLETED | Tofacitinib | 0 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | hypercholesterolemia | Investigations | Tofacitinib | 5 | 11 | 5 |
| other | Acne | Skin and subcutaneous tissue disorders | Tofacitinib | 4 | 11 | 5 |
| other | Headache | Musculoskeletal and connective tissue disorders | Tofacitinib | 1 | 11 | 1 |
| other | Fatique | Musculoskeletal and connective tissue disorders | Tofacitinib | 1 | 11 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Tofacitinib | 0 | 11 |
| Total, other adverse events | Tofacitinib | 5 | 11 |
| Total, serious adverse events | Tofacitinib | 0 | 11 |
Source ClinicalTrials.gov
Papers28
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06202560
GET https://conductscience.org/api/trials/v1/NCT06202560/papers?page=2